[go: up one dir, main page]

SG11202005320VA - Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid - Google Patents

Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid

Info

Publication number
SG11202005320VA
SG11202005320VA SG11202005320VA SG11202005320VA SG11202005320VA SG 11202005320V A SG11202005320V A SG 11202005320VA SG 11202005320V A SG11202005320V A SG 11202005320VA SG 11202005320V A SG11202005320V A SG 11202005320VA SG 11202005320V A SG11202005320V A SG 11202005320VA
Authority
SG
Singapore
Prior art keywords
compositions
aqueous solution
injectable aqueous
human glucagon
copolyamino acid
Prior art date
Application number
SG11202005320VA
Inventor
You-Ping Chan
Alexandre Geissler
Romain Noel
Richard Charvet
Nicolas Laurent
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1761809A external-priority patent/FR3074683B1/en
Application filed by Adocia filed Critical Adocia
Priority claimed from PCT/EP2018/084065 external-priority patent/WO2019110837A1/en
Publication of SG11202005320VA publication Critical patent/SG11202005320VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
    • C08L77/04—Polyamides derived from alpha-amino carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyamides (AREA)
SG11202005320VA 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid SG11202005320VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762606137P 2017-12-07 2017-12-07
FR1761809A FR3074683B1 (en) 2017-12-07 2017-12-07 COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
FR1855939 2018-06-29
PCT/EP2018/084065 WO2019110837A1 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid

Publications (1)

Publication Number Publication Date
SG11202005320VA true SG11202005320VA (en) 2020-07-29

Family

ID=64899248

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005320VA SG11202005320VA (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid

Country Status (10)

Country Link
US (1) US11191812B2 (en)
EP (1) EP3720471B1 (en)
JP (1) JP2021505597A (en)
KR (1) KR20200107951A (en)
CN (1) CN111670042A (en)
AU (1) AU2018380993A1 (en)
BR (1) BR112020011484A2 (en)
CA (1) CA3084700A1 (en)
MA (1) MA51017A (en)
SG (1) SG11202005320VA (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019110788A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
CA3084688A1 (en) 2017-12-07 2019-06-13 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
US11633460B2 (en) 2017-12-07 2023-04-25 Adocia Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
CN112608378B (en) * 2020-12-09 2023-09-08 江苏师范大学 A class of GLP-1/cholecystokinin-1 receptor dual agonists and their applications

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1202607A (en) 1968-01-10 1970-08-19 Novo Terapeutisk Labor As Improvements in or relating to stable glucagon solutions and their preparation
DE69918070T2 (en) 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilized, aqueous glucagon solutions containing detergents
FR2801226B1 (en) 1999-11-23 2002-01-25 Flamel Tech Sa COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR VECTORIZATION OF ACTIVE INGREDIENTS AND METHOD OF PREPARATION
FR2840614B1 (en) 2002-06-07 2004-08-27 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2860516B1 (en) * 2003-10-03 2006-01-13 Flamel Tech Sa TELECHELIC HOMOPOLYAMINOACIDES FUNCTIONALIZED BY HYDROPHOBIC GROUPS AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
WO2009049222A1 (en) * 2007-10-12 2009-04-16 Curedm, Inc. Compositions and methods of using the human proislet peptide receptor
ES2509883T3 (en) * 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Glucagon antagonists
US20110097386A1 (en) 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
WO2011138802A1 (en) 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd., Injection solution
EP2635296B1 (en) 2010-11-03 2014-12-24 Arecor Limited Novel composition comprising glucagon
WO2013101749A1 (en) 2011-12-29 2013-07-04 Latitude Pharmaceuticals, Inc. Stabilized glucagon nanoemulsions
WO2013104861A1 (en) 2012-01-09 2013-07-18 Adocia Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid)
WO2014096440A2 (en) 2012-12-21 2014-06-26 Novozymes Biopharma Dk A/S Composition
EP3082817A4 (en) 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions for drug administration
US9334316B2 (en) 2014-04-11 2016-05-10 Oregon Health & Science University Formulations comprising glucagon
FR3052071B1 (en) 2016-06-07 2018-09-07 Adocia COMPOSITIONS IN THE FORM OF AQUEOUS INJECTABLE SOLUTION COMPRISING GLUCAGON AND A CO-POLYAMINOACID
US10485851B2 (en) 2016-06-07 2019-11-26 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid

Also Published As

Publication number Publication date
BR112020011484A2 (en) 2020-11-17
AU2018380993A1 (en) 2020-06-11
EP3720471B1 (en) 2023-11-29
CN111670042A (en) 2020-09-15
KR20200107951A (en) 2020-09-16
US11191812B2 (en) 2021-12-07
CA3084700A1 (en) 2019-06-13
JP2021505597A (en) 2021-02-18
US20190275109A1 (en) 2019-09-12
MA51017A (en) 2021-03-17
EP3720471A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
IL275184A (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
IL272141A (en) Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor
ZA202000439B (en) Liposome compositions comprising weak acid drugs and uses thereof
SG11201604710XA (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
IL275206A (en) Dried implant composition and injectable aqueous implant formulation
IL274635A (en) Stable ascorbic acid compositions and methods of using the same
PT3509638T (en) Cannabidiolic acid esters compositions and uses thereof
SG11201608217PA (en) Fatty acid composition and use thereof
SG11202005320VA (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
IL266279A (en) Stable aqueous capsaicin injectable formuatlions and medical uses thereof
IL262036A (en) Hyaluronic acid conjugates and uses thereof
SMT202200386T1 (en) Palatable compositions including sodium phenylbutyrate and uses thereof
SG11202005319PA (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
PL2875832T3 (en) Implantable paste and its use
IL275146A (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
IL241357B (en) Site 2 insulin analogues and uses thereof
IL253600A0 (en) Insulin analogues and compositions comprising same
IL290166A (en) Collagen 7 compositions and use thereof
SG10202008700VA (en) α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
SG10202106375UA (en) Pharmaceutical compositions and use thereof
IL280389A (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
IL273967A (en) Aqueous compositions comprising bilastine and mometasone
HK40014614A (en) Stable aqueous capsaicin injectable formulations and medical uses thereof
GB201511863D0 (en) Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same